학술논문
Poster: IBCL-081 MAGNIFY Phase 3b Study of Lenalidomide + Rituximab (R2) Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Complete Induction Phase Analysis
Document Type
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S172-S172
Subject
Language
ISSN
2152-2650